BlackRock Posts Mixed Q3 Earnings; Bullish View On Immunovant
- October 13th, 2023
- 637 views
BlackRock, Inc. (NYSE: BLK), an investment management and financial services company, reported third-quarter 2023 adjusted earnings per share (EPS) of $10.91, surpassing the consensus EPS estimate of $8.26. However, the company's revenue for the period stood at $4.522 billion, slightly below analysts' expectations of $4.54 billion.
$BLK was trading at $630.00 in pre-market, reflecting a decrease of $6.17 (-0.97%).
In other news, UBS has upgraded Immunovant, Inc. (Nasdaq: IMVT), a biopharmaceutical company, from Neutral to Buy and raised the price target from $18 to $55.
Despite closing at $35.28 on Thursday, the adjusted price target indicates a potential upside of $19.72 or about 55.86% for $IMVT, based on the financial services firm's analysis
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)
Post Your Comments
Want To Find Some News?
Recent Posts
-
Countdown to Earnings: Qualcomm, McKesson, and Humana Take the Stage
November 03rd, 2025Earnings Preview: DoorDash, Cencora, and Fortinet in Focus
November 03rd, 2025Wall Street Eyes Palantir, Diamondback, and Hologic Ahead of Earnings
November 02nd, 2025Crown Equity Holdings, Inc. Announces Dissolution of Partnership with Herbal Works Inc.
November 02nd, 2025Cadence Design Systems, Celestica, and F5 Earnings Preview
October 26th, 2025
Member Login